GLS and Cognitive impairment: This study provides the first demonstration that systemically administered, microglia-targeted dendrimer-conjugated GLS1 inhibitors can selectively inhibit microglial GLS1 activity and improve stress-induced neurobehavioral and cognitive deficits in the CSDS model, while avoiding off-target toxicity commonly associated with conventional GLS1 inhibitors.